Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. News
Inhibrx Biosciences, Inc. Quantitative Score
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Inhibrx Biosciences, Inc. Financials
Table Compare
Compare INBX metrics with: | |||
|---|---|---|---|
Earnings & Growth | INBX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | INBX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | INBX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | INBX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Inhibrx Biosciences, Inc. Income
Inhibrx Biosciences, Inc. Balance Sheet
Inhibrx Biosciences, Inc. Cash Flow
Inhibrx Biosciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Inhibrx Biosciences, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.8500 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2024-06-20 | 0.85 | Quarterly |
Historical Market Cap
Shares Outstanding
Inhibrx Biosciences, Inc. Executives
| Name | Role |
|---|---|
| Kelly Devine Deck | Executive VP, CFO & Treasurer |
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman |
| Ashraf Amanullah | Executive VP & Chief Technical Operations Officer |
| Carlos Bais | EVice President & Chief Scientific Officer |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Kelly Devine Deck | Executive VP, CFO & Treasurer | Female | 1980 | 2.19M |
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | Male | 1967 | 1.13M |
| Ashraf Amanullah | Executive VP & Chief Technical Operations Officer | 1968 | -- | |
| Carlos Bais | EVice President & Chief Scientific Officer | -- | ||
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer | -- |
Inhibrx Biosciences, Inc. Insider Trades
| Date | 7 Oct |
| Name | VIKING GLOBAL INVESTORS LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 308643 |
| Date | 7 Oct |
| Name | VIKING GLOBAL INVESTORS LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 16315 |
| Date | 7 Oct |
| Name | VIKING GLOBAL INVESTORS LP |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 25042 |
| Date | 28 May |
| Name | MANHARD KIMBERLY |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 28 May |
| Name | Vuori Kristiina MD |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 7 Oct | VIKING GLOBAL INVESTORS LP | 10 percent owner | Disposed | S-Sale | 308643 |
| 7 Oct | VIKING GLOBAL INVESTORS LP | 10 percent owner | Disposed | S-Sale | 16315 |
| 7 Oct | VIKING GLOBAL INVESTORS LP | 10 percent owner | Disposed | S-Sale | 25042 |
| 28 May | MANHARD KIMBERLY | Director | Acquired | A-Award | 15000 |
| 28 May | Vuori Kristiina MD | Director | Acquired | A-Award | 15000 |